JP2013516450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516450A5 JP2013516450A5 JP2012547546A JP2012547546A JP2013516450A5 JP 2013516450 A5 JP2013516450 A5 JP 2013516450A5 JP 2012547546 A JP2012547546 A JP 2012547546A JP 2012547546 A JP2012547546 A JP 2012547546A JP 2013516450 A5 JP2013516450 A5 JP 2013516450A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition according
- composition
- protein
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 208000001756 Virus Disease Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 102100007517 C5 Human genes 0.000 claims 2
- 108010028773 Complement C5 Proteins 0.000 claims 2
- 208000006572 Human Influenza Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010022000 Influenza Diseases 0.000 claims 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N Leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 101700059544 PTGR1 Proteins 0.000 claims 2
- 206010047461 Viral infection Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000000295 complement Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000004193 respiratory failure Diseases 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- 206010069351 Acute lung injury Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010001053 Acute respiratory failure Diseases 0.000 claims 1
- 241000238421 Arthropoda Species 0.000 claims 1
- 206010064097 Avian influenza Diseases 0.000 claims 1
- 108010078546 Complement C5a Proteins 0.000 claims 1
- 206010069767 H1N1 influenza Diseases 0.000 claims 1
- 101710015954 HVA1 Proteins 0.000 claims 1
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- 101700065814 LEA2 Proteins 0.000 claims 1
- 101700021338 LEC Proteins 0.000 claims 1
- 101700077545 LECC Proteins 0.000 claims 1
- 101700028499 LECG Proteins 0.000 claims 1
- 101700063913 LECT Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028154 Multi-organ failure Diseases 0.000 claims 1
- 101710034340 Os04g0173800 Proteins 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002066 eicosanoids Chemical class 0.000 claims 1
- 101700036391 lecA Proteins 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 101700001016 mbhA Proteins 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
Description
方法
実施例１で上述したようにＢａｌｂＣマウスの感染及び処理を行った。
実施例１で上述したようにＢａｌｂＣマウスの感染及び処理を行った。
ＢＡＬＦ中のＣ５ａレベルの測定は、偽接種マウスでは 日目、ヒトＨ１Ｎ１ウイルスの亜致死量（１０4ＰＦＵ）に曝露したマウスでは１日目、４日目、７日目及び１０日目、ヒトＨ１Ｎ１ウイルスの致死量（１０6ＰＦＵ）に曝露したマウスでは１日目、３日目及び５日目に行った。
Claims (14)
- 気道のウイルス感染による炎症を治療又は予防するための組成物であって、
ａ）古典的補体経路、代替補体経路及びレクチン補体経路を阻害し、及び／又は
ｂ）エイコサノイド活性を阻害する、
治療有効量又は予防有効量の剤を含む前記組成物。 - 剤は補体Ｃ５と結合する、請求項１に記載の組成物。
- 剤は、Ｃ５転換酵素によって補体Ｃ５が補体Ｃ５ａと補体Ｃ５ｂ〜９（ＭＡＣ）へ切断されることを阻害する、請求項２に記載の組成物。
- 剤はＬＴＢ４と結合する、請求項１〜３のいずれか１項に記載の組成物。
- 剤は吸血性節足動物に由来する、請求項１〜４のいずれか１項に記載の組成物。
- 剤は、図２のアミノ酸配列のアミノ酸１９〜１６８を含むか又は該アミノ酸で構成されるタンパク質、又はこのタンパク質の機能等価物である、請求項１〜５のいずれか１項に記載の組成物。
- 剤は、図２のアミノ酸配列のアミノ酸１〜１６８を含むか又は該アミノ酸で構成されるタンパク質、又はこのタンパク質の機能等価物である、請求項１〜６のいずれか１項に記載の組成物。
- 剤は、請求項６又は７に記載のタンパク質をコードする核酸分子である、請求項１〜７のいずれか１項に記載の組成物。
- 核酸分子は、図２のヌクレオチド配列の塩基５３〜５０７を含むか又は該塩基で構成される、請求項８に記載の組成物。
- 核酸分子は、図２のヌクレオチド配列の塩基１〜５０７を含むか又は該塩基で構成される、請求項９に記載の組成物。
- 対象は哺乳動物であり、好ましくはヒトである、請求項１〜１０のいずれか１項に記載の組成物。
- 剤は、対象内で可能な限り多量の有効Ｃ５及び／又はＬＴＢ４（より好ましくは有効Ｃ５全量）と結合するのに十分な用量で投与する、請求項４〜１１のいずれか１項に記載の組成物。
- 気道のウイルス感染による炎症は、急性肺傷害や急性呼吸促迫症候群等の呼吸不全、又は多臓器不全等の呼吸不全の続発症である、請求項１〜１２のいずれか１項に記載の組成物。
- ウイルス感染は、インフルエンザＡＨ５Ｎ１（トリインフルエンザ）やインフルエンザＡＨ１Ｎ１（ブタインフルエンザ）等の汎発流行性インフルエンザウイルスやＳＡＲＳコロナウイルス等の上気道又は下気道の感染である、請求項１〜１３のいずれか１項に記載の組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1000318.4A GB201000318D0 (en) | 2010-01-08 | 2010-01-08 | Method of treatment |
| GB1000318.4 | 2010-01-08 | ||
| GB1005071.4 | 2010-03-25 | ||
| GBGB1005071.4A GB201005071D0 (en) | 2010-03-25 | 2010-03-25 | Method of treatment |
| PCT/GB2011/000022 WO2011083317A1 (en) | 2010-01-08 | 2011-01-10 | Ev576 for use in the treatment of viral infections of the respiratory tract |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516450A JP2013516450A (ja) | 2013-05-13 |
| JP2013516450A5 true JP2013516450A5 (ja) | 2014-02-13 |
| JP5840623B2 JP5840623B2 (ja) | 2016-01-06 |
Family
ID=44305222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547546A Active JP5840623B2 (ja) | 2010-01-08 | 2011-01-10 | 気道のウイルス感染症の治療に用いるｅｖ５７６ |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20120283167A1 (ja) |
| EP (1) | EP2521562B1 (ja) |
| JP (1) | JP5840623B2 (ja) |
| CN (1) | CN102762223B (ja) |
| AU (2) | AU2011204483B2 (ja) |
| CA (1) | CA2785612C (ja) |
| NZ (1) | NZ601018A (ja) |
| PL (1) | PL2521562T3 (ja) |
| WO (1) | WO2011083317A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015140304A1 (en) * | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| IL309975A (en) | 2016-06-14 | 2024-03-01 | Regeneron Pharma | Antibodies against C5 and their uses |
| PL3612208T3 (pl) | 2017-04-21 | 2023-07-24 | Volution Immuno Pharmaceuticals Sa | Coversin do leczenia autoimmunologicznych chorób pęcherzowych |
| CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| JP2022500389A (ja) | 2018-09-10 | 2022-01-04 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| GB201905810D0 (en) | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US11607428B2 (en) | 2019-06-06 | 2023-03-21 | Spiritus Therapeutics, Inc. | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| AU2019468121A1 (en) | 2019-09-27 | 2022-05-12 | Volution Immuno Pharmaceuticals Sa | Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20230005850A (ko) * | 2020-04-01 | 2023-01-10 | 티오제네시스 테라퓨틱스, 인크. | 베타코로나바이러스 감염의 치료를 위한 시스테아민 전구체 화합물 |
| EP4146168A4 (en) * | 2020-05-08 | 2024-06-12 | Kodiak Sciences Inc. | USE OF ANTI-IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017099A1 (en) | 1992-02-27 | 1993-09-02 | Merck & Co., Inc. | Protein for inhibiting collagen-stimulated platelet aggregation |
| US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| AU2004242759B2 (en) * | 2003-06-02 | 2009-11-26 | Volution Immuno Pharmaceuticals Sa | Complement inhibitors from ticks |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| US7274999B1 (en) * | 2006-03-10 | 2007-09-25 | Atmel Corporation | Brownout detector system and method |
| MX2008013140A (es) * | 2006-04-12 | 2009-02-12 | Biocryst Pharm Inc | Tratamientos antivirales intramusculares. |
| CA2662716C (en) * | 2006-09-08 | 2017-11-21 | Varleigh Limited | Method of treating respiratory disorders |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
-
2011
- 2011-01-10 CN CN201180005464.6A patent/CN102762223B/zh active Active
- 2011-01-10 PL PL11700973T patent/PL2521562T3/pl unknown
- 2011-01-10 EP EP11700973.8A patent/EP2521562B1/en active Active
- 2011-01-10 AU AU2011204483A patent/AU2011204483B2/en active Active
- 2011-01-10 NZ NZ601018A patent/NZ601018A/xx unknown
- 2011-01-10 WO PCT/GB2011/000022 patent/WO2011083317A1/en active Application Filing
- 2011-01-10 JP JP2012547546A patent/JP5840623B2/ja active Active
- 2011-01-10 CA CA2785612A patent/CA2785612C/en active Active
- 2011-01-10 US US13/521,011 patent/US20120283167A1/en not_active Abandoned
-
2015
- 2015-01-02 US US14/588,616 patent/US9522171B2/en active Active
-
2016
- 2016-05-11 AU AU2016203058A patent/AU2016203058B2/en active Active
- 2016-07-22 US US15/217,601 patent/US20170065677A1/en not_active Abandoned
-
2019
- 2019-06-07 US US16/434,737 patent/US20200155646A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516450A5 (ja) | ||
| Honce et al. | Obesity-related microenvironment promotes emergence of virulent influenza virus strains | |
| Lamichhane et al. | The role of innate leukocytes during influenza virus infection | |
| Hui et al. | The role of adjuvant immunomodulatory agents for treatment of severe influenza | |
| Rajao et al. | Swine as a model for influenza A virus infection and immunity | |
| Ilyushina et al. | Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia | |
| Tuvim et al. | Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia | |
| Florescu et al. | The complex link between influenza and severe sepsis | |
| Yen et al. | Pandemic influenza as a current threat | |
| Govorkova et al. | Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells | |
| CY1122291T1 (el) | Αναστολeις ιικου αναδιπλασιασμου | |
| KR101440629B1 (ko) | 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들 | |
| Marathe et al. | Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A (H5N1) virus infection in mice | |
| Ludwig | Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections | |
| Choi et al. | Differential microRNA expression following infection with a mouse-adapted, highly virulent avian H5N2 virus | |
| Shapshak et al. | The influenza pandemic of 2009: lessons and implications | |
| JP2009518410A5 (ja) | ||
| Cai et al. | 14-Deoxy-11, 12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A (H5N1) influenza viruses | |
| Yang et al. | Lianhua‐Qingwen Displays Antiviral and Anti‐Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model | |
| Bray | Highly pathogenic RNA viral infections: challenges for antiviral research | |
| Noah et al. | Adapting global influenza management strategies to address emerging viruses | |
| Kahn et al. | Swine and influenza: a challenge to one health research | |
| JP2014510130A5 (ja) | ||
| JP2013503880A5 (ja) | ||
| CN111163792A (zh) | 用于治疗病毒感染的肽 |